Supprelin La is owned by Endo Pharm.
Supprelin La contains Histrelin Acetate.
Supprelin La has a total of 1 drug patent out of which 0 drug patents have expired.
Supprelin La was authorised for market use on 03 May, 2007.
Supprelin La is available in implant;subcutaneous dosage forms.
Supprelin La can be used as method of treatment of children with central precocious puberty.
The generics of Supprelin La are possible to be released after 16 June, 2026.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8062652||ENDO PHARM||Compositions and methods for treating precocious puberty|| |
(3 years from now)
Market Authorisation Date: 03 May, 2007
Treatment: Method of treatment of children with central precocious puberty
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic